4.6 Article

Montelukast Inhibits HCoV-OC43 Infection as a Viral Inactivator

Journal

VIRUSES-BASEL
Volume 14, Issue 5, Pages -

Publisher

MDPI
DOI: 10.3390/v14050861

Keywords

montelukast; HCoV-OC43; viral inactivator

Categories

Funding

  1. Shanghai Public Health Clinical Center [KY-GW-2017-17]

Ask authors/readers for more resources

This study found that the leukotriene receptor antagonist montelukast can effectively inhibit the infection of HCoV-OC43 and induce the release of viral RNA by disrupting the viral lipid membrane, suggesting its potential as a treatment for human beta-coronavirus infection.
Coronaviruses (CoVs) consist of a large group of RNA viruses causing various diseases in humans and in lots of animals. Human coronavirus (HCoV) OC43, the prototype of beta-coronavirus discovered in the 1960s, has been circulating in humans for long time, and infection with other emerging strains of beta-coronavirus (SARS-CoV, SARS-CoV-2, and MERS-CoV) can lead to severe illness and death. In this study, we found that montelukast, a leukotriene receptor antagonist, potently inhibited the infection of HCoV-OC43 in distinct cells in a dose- and time- dependent manner. Additionally, the results showed that montelukast induced release of HCoV-OC43 genomic RNA by disrupting the integrity of the viral lipid membrane, and irreversibly inhibited viral infection. Considering the similarity among HCoV-OC43, MERS-CoV, and SARS-CoV-2, it suggests that montelukast may be a potential candidate for the treatment of human beta-coronavirus infection.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available